Compare · NVS vs PHVS
NVS vs PHVS
Side-by-side comparison of Novartis AG (NVS) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 120.5x PHVS ($2.43B).
- PHVS has hit the wire 10 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 14 for PHVS).
- Company
- Novartis AG
- Pharvaris N.V.
- Price
- -
- -
- Market cap
- $293.40B
- $2.43B
- 1M return
- -
- +10.98%
- 1Y return
- -
- +48.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 10
- Recent ratings
- 25
- 14
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
Latest PHVS
- Chief Executive Officer Modig Berndt sold $80,154 worth of shares (2,292 units at $34.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 132,917 units (SEC Form 4)
- Wells Fargo initiated coverage on Pharvaris N.V. with a new price target
- Chief Medical Officer Lu Peng covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.34% to 65,405 units (SEC Form 4) (tax withholding)
- SEC Form 144 filed by Pharvaris N.V.
- Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
- Director Schikan Johannes Gerardus Christiaan Petrus sold $1,331,496 worth of shares (37,600 units at $35.41) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 315,167 units (SEC Form 4)
- Chief Early Development Lesage Anne exercised 38,472 shares at a strike of $6.85 and sold $2,695,452 worth of shares (76,172 units at $35.39) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 58,750 units (SEC Form 4)
- Chief Early Development Lesage Anne exercised 2,300 shares at a strike of $4.73 and sold $161,560 worth of shares (4,600 units at $35.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Schikan Johannes Gerardus Christiaan Petrus sold $84,250 worth of shares (2,400 units at $35.10) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 352,767 units (SEC Form 4)
- Chief Medical Officer Lu Peng exercised 29,700 shares at a strike of $2.59 and sold $1,018,832 worth of shares (29,700 units at $34.30) as part of a pre-agreed trading plan (SEC Form 4)